Characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/38027
• EU PAS number:
  EUPAS38026
• Study ID:
  38027
• Official title and acronym:
  Characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  The study aimed to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk, including: 1) describe the proportion of Chinese diabetic/non-diabetic patients with established cardiovascular disease, CKD, or at high cardiovascular risk including hypertension and hyperlipidaemia, 2) describe the demographic and clinical characteristics of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk, 3) investigate the treatment patterns of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk, 4) examine economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk, 5) explore the trends of clinical characteristics, treatment pattern, economic burden of inpatients over time (2015 and 2019 separately)
• Study status:
  Planned

Research institutions and networks

Institutions

West China Hospital

Study timelines

Date when funding contract was signed

Planned: 01/12/2020

Study start date

Planned: 30/11/2020

Data analysis start date

Planned: 01/09/2021

Date of final study report

Planned: 30/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable